Cancer Stem Cells Provide New Insights into the Therapeutic Responses of Human Prostate Cancer

Chapter
First Online:

Abstract

Whilst there has been a dramatic improvement in the survival of men with prostate cancer in the last few decades, we find ourselves at a crossroads, where another significant therapeutic advance is required. Current treatments for prostate cancer including hormone therapy, radiotherapy and chemotherapy all have their place, but result in almost inevitable treatment failure. In this chapter, we describe the role of cancer stem cells in tumour relapse as well as the potential they provide to develop novel treatment strategies. We examine the clinical implications of cancer stem cells as a therapy-resistant pool within prostate tumours and propose three strategies to target both cancer stem cells and bulk tumour cells, namely, combination therapy, differentiation therapy and targeted therapy. This chapter summarises the challenge of designing future therapies taking into account both the heterogeneity of prostate cancers and the resistant cancer stem cells at their core.

Keywords

Prostate Cancer Androgen Receptor Cancer Stem Cell Prostate Cancer Treatment Normal Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

Our research in prostate cancer stem cells was supported by programme and project grants from Yorkshire Cancer Research (Registered Charity 516898).

References

  1. Aggarwal BB, Sung B (2011) NF-kappaB in cancer: a matter of life and death. Cancer Discov 1:469–471PubMedGoogle Scholar
  2. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834–846PubMedGoogle Scholar
  3. Altieri DC (2012) Targeting survivin in cancer. Canc Lett. http://dx.doi.org/10.1016/j.conlet.2012.03.005
  4. An J, Chervin AS, Nie A, Ducoff HS, Huang Z (2007) Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 26:652–661PubMedGoogle Scholar
  5. Azevedo A, Cunha V, Teixeira AL, Medeiros R (2011) IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2:384–396PubMedGoogle Scholar
  6. Badros AZ (2010) The role of maintenance therapy in the treatment of multiple myeloma. J Natl Compr Canc Netw 8(Suppl 1):S21–27PubMedGoogle Scholar
  7. Bastus NC, Boyd LK, Mao X, Stankiewicz E, Kudahetti SC et al (2010) Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 70:9544–9548PubMedGoogle Scholar
  8. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A et al (2008) Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 9:R83PubMedGoogle Scholar
  9. Blackwood JK, Williamson SC, Greaves LC, Wilson L, Rigas AC et al (2011) In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells. J Pathol 225:181–188PubMedGoogle Scholar
  10. Bluemn EG, Nelson PS (2012) The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 24:251–257PubMedGoogle Scholar
  11. Bonkhoff H (2012) Factors implicated in radiation therapy failure and radiosensitization of prostate cancer. Prostate Canc 2012: 593241Google Scholar
  12. Bragado P, Sosa MS, Keely P, Condeelis J, Aguirre-Ghiso JA (2012) Microenvironments dictating tumor cell dormancy. Recent Results Cancer Res (Fortschritte der Krebsforschung Progres dans les recherches sur le cancer) 195:25–39Google Scholar
  13. Brawer MK (2002) Radiation therapy failure in prostate cancer patients: risk factors and methods of detection. Rev Urol 4(Suppl 2):S2–S11PubMedGoogle Scholar
  14. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q et al (2011) Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19:664–678PubMedGoogle Scholar
  15. Brunner TB, Kunz-Schughart LA, Grosse-Gehling P, Baumann M (2012) Cancer stem cells as a predictive factor in radiotherapy. Semin Radiat Oncol 22:151–174PubMedGoogle Scholar
  16. Buczacki S, Davies RJ, Winton DJ (2011) Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target. Br J Cancer 105:1253–1259PubMedGoogle Scholar
  17. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM et al (2010) Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 102:1637–1652PubMedGoogle Scholar
  18. Chen Y, Li D, Wang D, Liu X, Yin N et al (2012) Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells. J Cell Biochem 113(12): 3643–3652PubMedGoogle Scholar
  19. Cheng L, Bostwick DG, Li G, Wang Q, Hu N et al (1999) Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer 85:2017–2022PubMedGoogle Scholar
  20. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951PubMedGoogle Scholar
  21. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H et al (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109:2784–2789PubMedGoogle Scholar
  22. Cook JA, Gius D, Wink DA, Krishna MC, Russo A et al (2004) Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 14:259–266PubMedGoogle Scholar
  23. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM et al (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106:13820–13825PubMedGoogle Scholar
  24. Cruz FD, Matushansky I (2012) Solid tumor differentiation therapy - is it possible? Oncotarget 3:559–567PubMedGoogle Scholar
  25. Dai Y, Bae K, Siemann DW (2011) Impact of hypoxia on the metastatic potential of human prostate cancer cells. Int J Radiat Oncol Biol Phys 81:521–528PubMedGoogle Scholar
  26. De Marzo AM, Meeker AK, Epstein JI, Coffey DS (1998) Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 153:911–919PubMedGoogle Scholar
  27. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H et al (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256–269PubMedGoogle Scholar
  28. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284PubMedGoogle Scholar
  29. Dehm SM, Tindall DJ (2011) Alternatively spliced androgen receptor variants. Endocr Relat Cancer 18:R183–196PubMedGoogle Scholar
  30. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469–5477PubMedGoogle Scholar
  31. Di Stefano AB, Iovino F, Lombardo Y, Eterno V, Hoger T et al (2010) Survivin is regulated by interleukin-4 in colon cancer stem cells. J Cell Physiol 225:555–561PubMedGoogle Scholar
  32. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780–783PubMedGoogle Scholar
  33. Ding XW, Wu JH, Jiang CP (2010) ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86:631–637PubMedGoogle Scholar
  34. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC et al (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481:506–510PubMedGoogle Scholar
  35. Djavan B, Susani M, Bursa B, Basharkhah A, Simak R et al (1999) Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol 5:139–142PubMedGoogle Scholar
  36. Drachenberg DE (2000) Treatment of prostate cancer: watchful waiting, radical prostatectomy, and cryoablation. Semin Surg Oncol 18:37–44PubMedGoogle Scholar
  37. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J et al (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3:e2428PubMedGoogle Scholar
  38. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G et al (1995) Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1:1111–1118PubMedGoogle Scholar
  39. Elliott A, Adams J, Al-Hajj M (2010) The ABCs of cancer stem cell drug resistance. IDrugs 13:632–635PubMedGoogle Scholar
  40. Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF et al (2012) The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 118(23):5955–5963PubMedGoogle Scholar
  41. Frame FM, Hager S, Pellacani D, Stower MJ, Walker HF et al (2010) Development and limitations of lentivirus vectors as tools for tracking differentiation in prostate epithelial cells. Exp Cell Res 316:3161–3171PubMedGoogle Scholar
  42. Fulda S, Pervaiz S (2010) Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol 42:31–38PubMedGoogle Scholar
  43. Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig Z et al (2012) Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells 30:1076–1086PubMedGoogle Scholar
  44. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567PubMedGoogle Scholar
  45. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON (2010a) Identification of a cell of origin for human prostate cancer. Science 329:568–571PubMedGoogle Scholar
  46. Goldstein AS, Stoyanova T, Witte ON (2010b) Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol 4:385–396PubMedGoogle Scholar
  47. Haapala K, Kuukasjarvi T, Hyytinen E, Rantala I, Helin HJ et al (2007) Androgen receptor ­amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 38:474–478PubMedGoogle Scholar
  48. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R et al (2010) Androgen-induced TOP2B-­mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 42:668–675PubMedGoogle Scholar
  49. Hay CW, McEwan IJ (2012) The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One 7:e32514PubMedGoogle Scholar
  50. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276–308PubMedGoogle Scholar
  51. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L et al (2009) DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5:168–177PubMedGoogle Scholar
  52. Hudson DL, Guy AT, Fry P, O'Hare MJ, Watt FM et al (2001) Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 49:271–278PubMedGoogle Scholar
  53. Isaacs JT, Coffey DS (1981) Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41:5070–5075PubMedGoogle Scholar
  54. Isaacs JT, Coffey DS (1989) Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 2:33–50Google Scholar
  55. Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J et al (2010) Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 7:279–282PubMedGoogle Scholar
  56. Ishkanian AS, Zafarana G, Thoms J, Bristow RG (2010) Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncologica 49:888–894PubMedGoogle Scholar
  57. Jewett A, Tseng HC (2012) Potential rescue, survival and differentiation of cancer stem cells and primary non-transformed stem cells by monocyte-induced split anergy in natural killer cells. Cancer Immunol Immunother 61:265–274PubMedGoogle Scholar
  58. Jewett A, Tseng HC, Arasteh A, Saadat S, Christensen RE et al (2012) Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells. Curr Drug Deliv 9:5–16PubMedGoogle Scholar
  59. Jones JS (2011) Radiorecurrent prostate cancer: an emerging and largely mismanaged epidemic. Eur Urol 60(3):411–412PubMedGoogle Scholar
  60. Kallioniemi OP, Visakorpi T (1996) Genetic basis and clonal evolution of human prostate cancer. Adv Cancer Res 68:225–255PubMedGoogle Scholar
  61. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D et al (2004) Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431:707–712PubMedGoogle Scholar
  62. Kelly K, Yin JJ (2008) Prostate cancer and metastasis initiating stem cells. Cell Res 18:528–537PubMedGoogle Scholar
  63. Kirby M, Hirst C, Crawford ED (2011) Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 65:1180–1192PubMedGoogle Scholar
  64. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E et al (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314–319PubMedGoogle Scholar
  65. Koutras AK, Starakis I, Lymperatou D, Kalofonos HP (2012) Angiogenesis as a therapeutic target in breast cancer. Mini Rev Med Chem 12(12):1230–1238PubMedGoogle Scholar
  66. Kubota Y (2012) Tumor angiogenesis and anti-angiogenic therapy. Keio J Med 61:47–56PubMedGoogle Scholar
  67. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C et al (2011) Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci USA 108:17087–17092PubMedGoogle Scholar
  68. Kusumbe AP, Bapat SA (2009) Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 69:9245–9253PubMedGoogle Scholar
  69. Kyprianou N, Isaacs JT (1988) Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552–562PubMedGoogle Scholar
  70. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645–648PubMedGoogle Scholar
  71. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J et al (2010) Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci USA 107:2610–2615PubMedGoogle Scholar
  72. Lee SO, Lou W, Hou M, Onate SA, Gao AC (2003) Interleukin-4 enhances prostate-specific ­antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 22:7981–7988PubMedGoogle Scholar
  73. Lee SO, Pinder E, Chun JY, Lou W, Sun M et al (2008) Interleukin-4 stimulates androgen-­independent growth in LNCaP human prostate cancer cells. Prostate 68:85–91PubMedGoogle Scholar
  74. Lee SO, Chun JY, Nadiminty N, Lou W, Feng S et al (2009) Interleukin-4 activates androgen receptor through CBP/p300. Prostate 69:126–132PubMedGoogle Scholar
  75. Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J et al (2012a) Abiraterone inhibits 3beta-­hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res 18:3571–3579PubMedGoogle Scholar
  76. Li L, Li B, Shao J, Wang X (2012b) Chemotherapy sorting can be used to identify cancer stem cell populations. Mol Biol Rep 39(11):9955–9963PubMedGoogle Scholar
  77. Limas C, Frizelle SP (1994) Proliferative activity in benign and neoplastic prostatic epithelium. J Pathol 174:201–208PubMedGoogle Scholar
  78. Liu G, Yuan X, Zeng Z, Tunici P, Ng H et al (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67PubMedGoogle Scholar
  79. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC et al (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407–6415PubMedGoogle Scholar
  80. Ma I, Allan AL (2011) The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells. Stem Cell Rev 7(2):292–306PubMedGoogle Scholar
  81. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G et al (2011) Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One 6:e29170PubMedGoogle Scholar
  82. Maiolino A, Hungria VT, Garnica M, Oliveira-Duarte G, Oliveira LC et al (2012) Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol 87(10):948–952PubMedGoogle Scholar
  83. Maitland NJ, Collins A (2005) A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int 96:1219–1223PubMedGoogle Scholar
  84. Maitland NJ, Collins AT (2008) Inflammation as the primary aetiological agent of human prostate cancer: a stem cell connection? J Cell Biochem 105:931–939PubMedGoogle Scholar
  85. Maitland NJ, Collins AT (2010) Cancer stem cells— a therapeutic target? Curr Opin Mol Ther 12:662–673PubMedGoogle Scholar
  86. Maitland NJ, Frame FM, Polson ES, Lewis LJ, Collins AC (2011) Prostate cancer stem cells: do they have a basal or luminal phenotype? Horm Cancer 2(1):47–61PubMedGoogle Scholar
  87. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK et al (2009) Induced chromosomal proximity and gene fusions in prostate cancer. Science 326:1230PubMedGoogle Scholar
  88. Marcu M, Radu E, Sajin M (2010) Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance. Rom J Morphol Embryol 51:7–12PubMedGoogle Scholar
  89. Marin-Aguilera M, Codony-Servat J, Kalko SG, Fernandez PL, Bermudo R et al (2012) Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 11:329–339PubMedGoogle Scholar
  90. Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K et al (2005) Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment. Int J Cancer 117:221–229PubMedGoogle Scholar
  91. Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12:323–334PubMedGoogle Scholar
  92. Matei DV, Renne G, Pimentel M, Sandri MT, Zorzino L et al (2012) Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt. Clin Genitourin Cancer 10(3):164–173PubMedGoogle Scholar
  93. Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S et al (2012) Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-­resistance? Ann Oncol 23(11):2943–2947PubMedGoogle Scholar
  94. Miki J, Rhim JS (2008) Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. Prostate Cancer Prostatic Dis 11:32–39PubMedGoogle Scholar
  95. Milosevic M, Warde P, Menard C, Chung P, Toi A et al (2012) Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 18:2108–2114PubMedGoogle Scholar
  96. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK et al (1995) Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 147:92–101PubMedGoogle Scholar
  97. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447–4454PubMedGoogle Scholar
  98. Moore N, Lyle S (2011) Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol, 11 pages. doi: 10.1155/2011/396076Google Scholar
  99. Moore N, Houghton J, Lyle S (2012) Slow-cycling therapy-resistant cancer cells. Stem Cells Dev 21:1822–1830PubMedGoogle Scholar
  100. Munoz J, Stange DE, Schepers AG, van de Wetering M, Koo BK et al (2012) The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent ' + 4' cell markers. EMBO J 31(14):3079–3091PubMedGoogle Scholar
  101. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ et al (1999) p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161:304–308PubMedGoogle Scholar
  102. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B et al (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25:1696–1708PubMedGoogle Scholar
  103. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG (2007) Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44 + alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 67:6796–6805PubMedGoogle Scholar
  104. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M et al (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140:62–73PubMedGoogle Scholar
  105. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(−/low)/CD44+ breast cancer-­initiating cells to radiation. J Natl Cancer Inst 98:1777–1785PubMedGoogle Scholar
  106. Piekarz RL, Bates SE (2009) Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 15:3918–3926PubMedGoogle Scholar
  107. Pietra G, Manzini C, Vitale M, Balsamo M, Ognio E et al (2009) Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 21:793–801PubMedGoogle Scholar
  108. Pili R, Salumbides B, Zhao M, Altiok S, Qian D et al (2012) Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 106:77–84PubMedGoogle Scholar
  109. Qi Y, Li RM, Kong FM, Li H, Yu JP et al (2012) How do tumor stem cells actively escape from host immunosurveillance? Biochem Biophys Res Commun 420:699–703PubMedGoogle Scholar
  110. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM et al (2008) Efficient tumour ­formation by single human melanoma cells. Nature 456:593–598PubMedGoogle Scholar
  111. Rane J, Pellacani D, Maitland NJ (2012) Advanced prostate cancer: a case for adjuvant differentiation therapy. Nat Rev Urol 9:595–602PubMedGoogle Scholar
  112. Rehman Y, Rosenberg JE (2012) Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther 6:13–18PubMedGoogle Scholar
  113. Reichert S, Rodel C, Mirsch J, Harter PN, Tomicic MT et al (2011) Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol 101:51–58PubMedGoogle Scholar
  114. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434:843–850PubMedGoogle Scholar
  115. Risbridger GP, Taylor RA (2008) Minireview: regulation of prostatic stem cells by stromal niche in health and disease. Endocrinology 149:4303–4306PubMedGoogle Scholar
  116. Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A et al (2011) Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci USA 108:12054–12059PubMedGoogle Scholar
  117. Salm SN, Burger PE, Coetzee S, Goto K, Moscatelli D et al (2005) TGF-{beta} maintains dormancy of prostatic stem cells in the proximal region of ducts. J Cell Biol 170:81–90PubMedGoogle Scholar
  118. Sanchez P, Hernandez AM, Stecca B, Kahler AJ, DeGueme AM et al (2004) Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci USA 101:12561–12566PubMedGoogle Scholar
  119. Schroder F, Crawford ED, Axcrona K, Payne H, Keane TE (2012) Androgen deprivation therapy: past, present and future. BJU Int 109(Suppl 6):1–12PubMedGoogle Scholar
  120. Scotto KW (2003) Transcriptional regulation of ABC drug transporters. Oncogene 22:7496–7511PubMedGoogle Scholar
  121. Sebastian de Bono J, Sandhu S, Attard G (2011) Beyond hormone therapy for prostate cancer with PARP inhibitors. Cancer Cell 19:573–574PubMedGoogle Scholar
  122. Seiwert TY, Salama JK, Vokes EE (2007) The concurrent chemoradiation paradigm–general principles. Nat Clin Pract Oncol 4:86–100PubMedGoogle Scholar
  123. Sell S (2004) Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 51:1–28PubMedGoogle Scholar
  124. Seruga B, Ocana A, Tannock IF (2011) Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8:12–23PubMedGoogle Scholar
  125. Sharifi N, Kawasaki BT, Hurt EM, Farrar WL (2006) Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther 5:901–906PubMedGoogle Scholar
  126. Shi M, Guo XT, Shu MG, Chen FL, Li LW (2007) Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers. Med Hypotheses 69:33–35PubMedGoogle Scholar
  127. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A et al (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4):220–241PubMedGoogle Scholar
  128. Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA et al (2008) Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 8:4521–4533PubMedGoogle Scholar
  129. Snippert HJ, Clevers H (2011) Tracking adult stem cells. EMBO Rep 12:113–122PubMedGoogle Scholar
  130. Sottocornola R, Lo Celso C (2012) Dormancy in the stem cell niche. Stem Cell Res Ther 3:10PubMedGoogle Scholar
  131. Stark GR, Wahl GM (1984) Gene amplification. Annu Rev Biochem 53:447–491PubMedGoogle Scholar
  132. Swift SL, Burns JE, Maitland NJ (2010) Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res 70:347–356PubMedGoogle Scholar
  133. Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8:97–106PubMedGoogle Scholar
  134. Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T et al (2012) Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 72:1438–1448PubMedGoogle Scholar
  135. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y et al (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15:4234–4241PubMedGoogle Scholar
  136. Trerotola M, Rathore S, Goel HL, Li J, Alberti S et al (2010) CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am J Transl Res 2:135–144PubMedGoogle Scholar
  137. van der Pluijm G (2011) Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 48:37–43PubMedGoogle Scholar
  138. Verheij M, Vens C, van Triest B (2010) Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist Updat 13:29–43PubMedGoogle Scholar
  139. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768PubMedGoogle Scholar
  140. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K et al (2011) Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA 108:16062–16067PubMedGoogle Scholar
  141. Waltering KK, Urbanucci A, Visakorpi T (2012) Androgen receptor (AR) aberrations in castration-­resistant prostate cancer. Mol Cell Endocrinol 360(1–2):38–43PubMedGoogle Scholar
  142. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A et al (2010) Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem 109:726–736PubMedGoogle Scholar
  143. Wicha MS (2008) Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res 10:105PubMedGoogle Scholar
  144. Wright NA (2012) Stem cell identification-in vivo lineage analysis versus in vitro isolation and clonal expansion. J Pathol 227:255–266PubMedGoogle Scholar
  145. Xiao W, Graham PH, Power CA, Hao J, Kearsley JH et al (2012) CD44 is a biomarker associated with human prostate cancer radiation sensitivity. Clin Exp Metastasis 29:1–9PubMedGoogle Scholar
  146. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G et al (2010) Chronic DLL4 blockade induces vascular neoplasms. Nature 463:E6–7PubMedGoogle Scholar
  147. Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R et al (2001) Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta 1539:28–43PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  1. 1.YCR Cancer Research Unit, Department of BiologyUniversity of YorkHeslingtonUK

Personalised recommendations